OncoMatch/Clinical Trials/NCT07182149
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Is NCT07182149 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NRM-823 for hnscc.
Treatment: NRM-823 — This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Esophageal Carcinoma
Gastric Cancer
Ovarian Cancer
Non-Small Cell Lung Carcinoma
Cervical Cancer
Endometrial Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiac function
Adequate liver, renal, pulmonary, and cardiac function. Adequate hematologic function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Normunity Investigational Site · Denver, Colorado
- Normunity Investigational Site · New Haven, Connecticut
- Normunity Investigational Site · Minneapolis, Minnesota
- Normunity Investigational Site · Maumee, Ohio
- Normunity Investigational Site · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify